Section 5: Patient Safety and Quality Assurance 2022
DOI: 10.1136/ejhpharm-2022-eahp.261
|View full text |Cite
|
Sign up to set email alerts
|

5PSQ-022 Desensitisation protocol for adalimumab in arthropathic psoriasis: a case report

Abstract: particularly in treatment modifications of anxiolytics and sedatives.This study suggests that pharmacists may find it difficult to achieve anticholinergic burden reductions by suggesting AD changes to physicians and patients.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 0 publications
0
0
0
Order By: Relevance